IGC Pharma, Inc.
IGC Pharma, Inc.
Your view on IGC
Overview
What the company does, where it operates, and who runs it.
About IGC Pharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ram Mukunda
- Headquarters
- 10224 Falls Road, Potomac, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ram Mukunda
- Headquarters
- 10224 Falls Road, Potomac, MD, US
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness.
It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development.
In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for IGC Pharma, Inc., and the rating behind it. IGC last traded at $0.28; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for IGC Pharma, Inc.. Starting points for IGC Pharma, Inc.: EPS -$0.08, beta 0.49 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for IGC Pharma, Inc.. IGC Pharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for IGC Pharma, Inc.. Trailing twelve-month EPS for IGC Pharma, Inc. stands at -$0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for IGC Pharma, Inc.. IGC Pharma, Inc. has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
IGC Pharma, Inc. valued side by side against its closest peers. IGC Pharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold IGC Pharma, Inc., and how their positions are changing. At a $27.9M market value, institutional positions materially move IGC Pharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by IGC Pharma, Inc. executives and directors. Shares of IGC Pharma, Inc. have traded between $0.25 and $0.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming IGC Pharma, Inc.. IGC Pharma, Inc. is a $27.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming IGC Pharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for IGC Pharma, Inc.. Coverage tracks IGC Pharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.